Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last C$0.53 CAD
Change Today 0.00 / 0.00%
Volume 0.0
SQD On Other Exchanges
As of 3:45 PM 04/29/15 All times are local (Market data is delayed by at least 15 minutes).

sqi diagnostics inc (SQD) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/5/15 - C$0.71
52 Week Low
12/15/14 - C$0.27
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SQI DIAGNOSTICS INC (SQD)

Related News

No related news articles were found.

sqi diagnostics inc (SQD) Related Businessweek News

No Related Businessweek News Found

sqi diagnostics inc (SQD) Details

SQI Diagnostics Inc., a life sciences company, develops and commercializes proprietary technologies and products for advanced multiplexing diagnostics in Canada. The company’s proprietary microarray tests and automated instruments are designed to simplify antigen, protein, and antibody testing workflow. The company offers sqidworks diagnostic platform, a fully-automated microarray processing and analytical system; sqidlite bench-top system that offers laboratories with workflow solutions from dilutions through reporting to run protein and antibody multiplexed immunoassays; and sqid-X System, a semi-automated bench-top platform, which incorporates SQI’s technology with the exception of automated fluidics handling. It also provides Ig_plex microarrays that discriminate between individual isotypes of antibodies and antigens, and proteins within a single well of a microarray resulting in the measurement of multiple biomarkers in a single test; and Ig_plex CHEX technology, which offers various in-microarray checks to ensure that the test has been completed without system, control, calibration, or microarray-related errors. The company serves clinical, academic, diagnostic, and pharmaceutical laboratories. Its products are used in immunogenicity and bioanalysis, IVD and clinical, biomarkers, and assay development applications. SQI Diagnostics Inc. is headquartered in Toronto, Canada.

33 Employees
Last Reported Date: 12/17/14

sqi diagnostics inc (SQD) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: C$276.9K
Vice President of Technology and Vice Preside...
Total Annual Compensation: C$129.2K
Director of Finance & Administration
Total Annual Compensation: C$115.0K
Vice President of Research and Development
Total Annual Compensation: C$203.1K
Compensation as of Fiscal Year 2014.

sqi diagnostics inc (SQD) Key Developments

SQI Diagnostics Inc. Presents at Bloom Burton & Co. Inc. Healthcare Investor Conference, May-04-2015 10:00 AM

SQI Diagnostics Inc. Presents at Bloom Burton & Co. Inc. Healthcare Investor Conference, May-04-2015 10:00 AM. Venue: Sheraton Centre Toronto Hotel (Corner of York and Queen St. West), Toronto, Ontario, M5H 3M9, Canada.

SQI Diagnostics Inc. Delivers Sqidlite System to Global Pharmaceutical Customer

SQI Diagnostics Inc. announced the delivery and installation of a sqidlite™ system under the terms of an agreement with a global pharmaceutical customer. As previously disclosed, two custom immunogenicity assays have been successfully developed for this customer. SQI has executed an agreement to install the fully automated sqidlite system at one of the customer's US-based facilities. Under the terms of the agreement, the customer will use the equipment primarily in order to validate the performance of a 21-plex test developed for this customer to run on SQI's sqidlite system. Successful, final evaluation is expected to result in the purchase of the sqidlite system and the on-going sales of initial products for use in the customer's clinical programs. The Company is currently in discussions to initiate development services for one or more additional products in 2015. The economic benefits of using SQI's custom tests with Ig_plex™ technology and sqidlite automated testing equipment in drug development are to decrease the total number of tests performed through multiplexing while at the same time requiring significantly less volume of valuable blood samples; reducing the total time required to process the tests resulting in significantly reduced labour costs and testing timelines. All of this has a significant impact on the customer's total cost of testing in the related clinical phases of their drug development programs. SQI's Ig_plex products have been shown to significantly improve the drug tolerance, sensitivity and other important performance metrics through the use of its custom anti-drug-antibody (ADA) tests, ultimately resulting in better, more cost effective, and easier to obtain data.

SQI Diagnostics Inc. Approves Board Appointments

SQI Diagnostics Inc. announced the annual and special meeting of shareholders held on April 8, 2015, the shareholders elected Clive J. Beddoe, Gerald R. Connor, Wilmot L. Matthews and Cameron R. Prange as directors.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SQD:CN C$0.53 CAD 0.00

SQD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SQD.
View Industry Companies

Industry Analysis


Industry Average

Valuation SQD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 216.2x
Price/Book 10.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 213.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SQI DIAGNOSTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at